Cargando…
Mapping oncogenic protein interactions for precision medicine
Normal protein‐protein interactions (normPPIs) occur with high fidelity to regulate almost every physiological process. In cancer, this highly organised and precisely regulated network is disrupted, hijacked or reprogrammed resulting in oncogenic protein‐protein interactions (oncoPPIs). OncoPPIs, wh...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306658/ https://www.ncbi.nlm.nih.gov/pubmed/35113472 http://dx.doi.org/10.1002/ijc.33954 |
_version_ | 1784752589988954112 |
---|---|
author | Sharifi Tabar, Mehdi Francis, Habib Yeo, Dannel Bailey, Charles G. Rasko, John E. J. |
author_facet | Sharifi Tabar, Mehdi Francis, Habib Yeo, Dannel Bailey, Charles G. Rasko, John E. J. |
author_sort | Sharifi Tabar, Mehdi |
collection | PubMed |
description | Normal protein‐protein interactions (normPPIs) occur with high fidelity to regulate almost every physiological process. In cancer, this highly organised and precisely regulated network is disrupted, hijacked or reprogrammed resulting in oncogenic protein‐protein interactions (oncoPPIs). OncoPPIs, which can result from genomic alterations, are a hallmark of many types of cancers. Recent technological advances in the field of mass spectrometry (MS)‐based interactomics, structural biology and drug discovery have prompted scientists to identify and characterise oncoPPIs. Disruption of oncoPPI interfaces has become a major focus of drug discovery programs and has resulted in the use of PPI‐specific drugs clinically. However, due to several technical hurdles, studies to build a reference oncoPPI map for various cancer types have not been undertaken. Therefore, there is an urgent need for experimental workflows to overcome the existing challenges in studying oncoPPIs in various cancers and to build comprehensive reference maps. Here, we discuss the important hurdles for characterising oncoPPIs and propose a three‐phase multidisciplinary workflow to identify and characterise oncoPPIs. Systematic identification of cancer‐type‐specific oncogenic interactions will spur new opportunities for PPI‐focused drug discovery projects and precision medicine. |
format | Online Article Text |
id | pubmed-9306658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93066582022-07-28 Mapping oncogenic protein interactions for precision medicine Sharifi Tabar, Mehdi Francis, Habib Yeo, Dannel Bailey, Charles G. Rasko, John E. J. Int J Cancer Review Normal protein‐protein interactions (normPPIs) occur with high fidelity to regulate almost every physiological process. In cancer, this highly organised and precisely regulated network is disrupted, hijacked or reprogrammed resulting in oncogenic protein‐protein interactions (oncoPPIs). OncoPPIs, which can result from genomic alterations, are a hallmark of many types of cancers. Recent technological advances in the field of mass spectrometry (MS)‐based interactomics, structural biology and drug discovery have prompted scientists to identify and characterise oncoPPIs. Disruption of oncoPPI interfaces has become a major focus of drug discovery programs and has resulted in the use of PPI‐specific drugs clinically. However, due to several technical hurdles, studies to build a reference oncoPPI map for various cancer types have not been undertaken. Therefore, there is an urgent need for experimental workflows to overcome the existing challenges in studying oncoPPIs in various cancers and to build comprehensive reference maps. Here, we discuss the important hurdles for characterising oncoPPIs and propose a three‐phase multidisciplinary workflow to identify and characterise oncoPPIs. Systematic identification of cancer‐type‐specific oncogenic interactions will spur new opportunities for PPI‐focused drug discovery projects and precision medicine. John Wiley & Sons, Inc. 2022-02-14 2022-07-01 /pmc/articles/PMC9306658/ /pubmed/35113472 http://dx.doi.org/10.1002/ijc.33954 Text en © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Sharifi Tabar, Mehdi Francis, Habib Yeo, Dannel Bailey, Charles G. Rasko, John E. J. Mapping oncogenic protein interactions for precision medicine |
title | Mapping oncogenic protein interactions for precision medicine |
title_full | Mapping oncogenic protein interactions for precision medicine |
title_fullStr | Mapping oncogenic protein interactions for precision medicine |
title_full_unstemmed | Mapping oncogenic protein interactions for precision medicine |
title_short | Mapping oncogenic protein interactions for precision medicine |
title_sort | mapping oncogenic protein interactions for precision medicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306658/ https://www.ncbi.nlm.nih.gov/pubmed/35113472 http://dx.doi.org/10.1002/ijc.33954 |
work_keys_str_mv | AT sharifitabarmehdi mappingoncogenicproteininteractionsforprecisionmedicine AT francishabib mappingoncogenicproteininteractionsforprecisionmedicine AT yeodannel mappingoncogenicproteininteractionsforprecisionmedicine AT baileycharlesg mappingoncogenicproteininteractionsforprecisionmedicine AT raskojohnej mappingoncogenicproteininteractionsforprecisionmedicine |